Department of Surgical Oncology & General Surgery, the First Hospital of China Medical University, Shenyang 110001, PR China.
Future Oncol. 2017 Nov;13(27):2489-2501. doi: 10.2217/fon-2017-0310. Epub 2017 Nov 10.
Neoadjuvant therapies are effective for local control and tumor downstaging. Up to date, preoperative long-course chemoradiotherapy and short-course radiotherapy are the two primary guideline-recommended neoadjuvant therapies for locally advanced rectal cancer patients. However, clinicians throughout the world are trying their best to further optimize the regimens and concepts of neoadjuvants. Hence, there is an urgent need to summarize evidence regarding indications of neaoadjuvant therapies and relative merits of current standard regimens. In addition, we also reviewed the optimized regimens mainly based on short-course radiotherapy with delayed surgery, consolidation chemotherapy, induction chemotherapy, chemotherapy alone without radiation and concepts in terms of organ preservation and personalized treatments to further explore the future evolution of neoadjuvant therapies in rectal cancer.
新辅助治疗对于局部控制和肿瘤降期有效。迄今为止,术前长程放化疗和短程放疗是局部晚期直肠癌患者两种主要的指南推荐的新辅助治疗方法。然而,全球的临床医生都在努力进一步优化新辅助治疗的方案和理念。因此,迫切需要总结新辅助治疗的适应证和当前标准方案的相对优势的证据。此外,我们还综述了主要基于短程放疗后延迟手术、巩固化疗、诱导化疗、单纯化疗而不放疗以及器官保存和个体化治疗理念的优化方案,以进一步探讨直肠癌新辅助治疗的未来发展。